One Shot Vaccine
THE 1st REGISTERED COVID-19 VACCINE
PROVEN HUMAN ADENOVIRAL SECTOR THECHNOLOGY
Moscow, May 20, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the approval of the Russian single-dose Sputnik Light vaccine against coronavirus by the Ministry of Health of the Republic of Nicaragua.
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V. Sputnik Light demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered.
The data was obtained from Russians vaccinated with a single injection, having not received the second one for any reason during the mass vaccination program between December 5, 2020 and April 15, 2021. An efficacy level of near 80% is higher than that of many two-dose vaccines.
In February 2021, the two-dose Sputnik V vaccine was also approved for use in Nicaragua under the emergency use authorization procedure.
To date Sputnik V has been authorized in 66 countries with total population of over 3.2 billion people.
Ebola (*) vaccine developed by the Gamaleya Center
MERS (Middle East Respiratory Syndrome)* candidate vaccine developed by the Gamaleya Center
Start of work on Sputnik V (*)
Vaccine developed by the Gamaleya Center
Completion of phase 1-11 of clinical trials
Vaccine registration in Russia
Launch of unprecedented post-registration multinational Phase Ill clinical triaIs
on over 44,000 volunteers
Start of mass vaccine production in Russia
Start of global vaccine supplies
Global supply of vaccine over 1 bn doses
(*) Vector platform based on human adenoviruses
Bosnia and Herzegovina
Recognition from the Global Scientific Community
SPUTNIK Light - A VACCINE FOR ALL HUMAN KIND
Sputnik’s efficacy and safety results are validated by internationally peer reviewed data published in The Lancet
May 20, 2021
“Nicaragua is already using Sputnik V vaccine to protect the population. Emergency use authorization of Sputnik Light will help increase the range of anti-COVID tools of the country and advance with the vaccination campaign.”
Sputnik V and Sputnik Light have a number of key advantages:
Efficacy of Sputnik V is 97.6% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021;
Efficacy of Sputnik Light is 79.4% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with the single dose vaccine from December 5, 2020 to April 15, 2021;
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V;
The Sputnik V and Sputnik Light vaccines are based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
There are no strong allergies caused by Sputnik V.
The storage temperature of Sputnik V and Sputnik Light at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
of people vaccinated had virus-neutralizing
antibiotics on the 28th day after vaccination
of people vaccinated had antigen specific
lgG antibodies 28 days after vaccination
of people vaccinated had cell immune response to coronavirus S-protein
of people vaccinated with pre-existing immunity had their antibody level increase by more than 40 times 10 days after vaccination